CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY ®, in a Phase 1 Study in Patients with Solid Tumors
Source
Discover more from Walk Seeing Guy - Asia
Subscribe to get the latest posts sent to your email.
